Skip to Main Content

File this under “reversal of fortunes.”

Late last Friday, Momenta Pharmaceuticals disclosed that a Pfizer plant contracted to make a generic version of a best-selling multiple sclerosis medicine was slapped with a warning letter by the US Food and Drug Administration. This means Momenta will suffer an unspecified delay in winning approval to sell a larger dose of the drug than what is currently available and, consequently, will lose a chunk of a big market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.